Loading...
Lectin antagonists in infection, immunity, and inflammation.
Meiers, Joscha Siebs, Eike Zahorska, Eva Titz, Alexander
Meiers, Joscha
Siebs, Eike
Zahorska, Eva
Titz, Alexander
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2019-08-27
Submitted date
Files
Loading...
Original manuscript
Adobe PDF, 9.86 MB
Other Titles
Abstract
Lectins are proteins found in all domains of life with a plethora of biological functions, especially in the infection process, immune response, and inflammation. Targeting these carbohydrate-binding proteins is challenged by the fact that usually low affinity interactions between lectin and glycoconjugate are observed. Nature often circumvents this process through multivalent display of ligand and lectin. Consequently, the vast majority of synthetic antagonists are multivalently displayed native carbohydrates. At the cost of disadvantageous pharmacokinetic properties and possibly a reduced selectivity for the target lectin, the molecules usually possess very high affinities to the respective lectin through ligand epitope avidity. Recent developments include the advent of glycomimetic or allosteric small molecule inhibitors for this important protein class and their use in chemical biology and drug research. This evolution has culminated in the transition of the small molecule GMI-1070 into clinical phase III. In this opinion article, an overview of the most important developments of lectin antagonists in the last two decades with a focus on the last five years is given
Citation
Curr Opin Chem Biol. 2019 Aug 27;53:51-67. doi: 10.1016/j.cbpa.2019.07.005.
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
Description
Series/Report no.
ISSN
1879-0402
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International